{"schema_version":"secwatch.filing_event.v1","accession":"0001034842-26-000053","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2026-08-04T20:10:16+00:00","discovered_at":"2026-08-04T20:11:03.450144+00:00","generated_at":"2026-08-04T20:11:11.814947+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel Q2 net product sales $67M (+14% YoY); raises 2026 revenue guidance to $285-295M; in-licenses VEPPANU","bullets":["Q2 2026 total revenues $78.7M, net income $17.3M ($0.88 diluted EPS); prior year net income $59.6M included $40M non-cash Lilly revenue.","TAVALISSE sales $47.4M (+18% YoY), REZLIDHIA $8.9M (+27%), GAVRETO $10.7M (-10%).","In-licensed VEPPANU (vepdegestrant) from Arvinas/Pfizer for $70M upfront; U.S. launch expected mid-August 2026.","2026 revenue guidance raised to $285-295M (ex-VEPPANU) from $275-290M; contract revenue guidance increased to ~$30M.","Cash & investments $95.3M at June 30, 2026, down from $155.0M at Dec 31, 2025 due to VEPPANU upfront payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001034842-26-000053","json":"https://secwatch.observer/filing/0001034842-26-000053.json","markdown":"https://secwatch.observer/filing/0001034842-26-000053.md","text":"https://secwatch.observer/filing/0001034842-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/0001034842-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/rigl-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:11:11.814947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}